The impact of highly active antiretroviral therapy on HIV-specific immune functionSAAG, Michael S.AIDS (Supplement). 2001, Vol 15, Num 2, pp S4-S10, issn 1350-2840Article

Emtridtabine, a new antiretroviral agent with activity against HIV and hepatitis B virusSAAG, Michael S.Clinical infectious diseases. 2006, Vol 42, Num 1, pp 126-131, issn 1058-4838, 6 p.Article

The Role of Immunotherapy in the Treatment of HIVSAAG, Michael S; AUTRAN, Brigitte.AIDS (Supplement). 2001, Vol 15, Num 2, issn 1350-2840, 45 p.Serial Issue

Low-dose daily interleukin-2 immunotherapy : Accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicitySMITH, Kendall A.AIDS (Supplement). 2001, Vol 15, Num 2, pp S28-S35, issn 1350-2840Article

Immune restoration and CD4+ T-cell function with antiretroviral therapiesLEDERMAN, Michael M.AIDS (Supplement). 2001, Vol 15, Num 2, pp S11-S15, issn 1350-2840Article

The potential role of interleukin-2 in HIVMITSUYASU, Ronald T.AIDS (Supplement). 2001, Vol 15, Num 2, pp S22-S27, issn 1350-2840Article

Opt-Out Testing : Who Can Afford to Take Care of Patients with Newly Diagnosed HIV Infection?SAAG, Michael S.Clinical infectious diseases. 2007, Vol 45, issn 1058-4838, S261-S265, SUP4Article

Health Care System and Policy Factors Influencing Engagement in HIV Medical Care: Piecing Together the Fragments of a Fractured Health Care Delivery SystemMUGAVERO, Michael J; NORTON, Wynne E; SAAG, Michael S et al.Clinical infectious diseases. 2011, Vol 52, issn 1058-4838, S238-S246, SUP2Article

Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practiceHOESLEY, Craig J; SAAG, Michael S; CHATHAM, Ashlee et al.Clinical infectious diseases. 2000, Vol 31, Num 4, pp 1095-1097, issn 1058-4838Article

Cellular immune response to human immunodeficiency virusNORRIS, Philip J; ROSENBERG, Eric S.AIDS (Supplement). 2001, Vol 15, Num 2, pp S16-S21, issn 1350-2840Article

Perspectives on inducing efficient immune control of HIV-1 replication : a new goal for HIV therapeutics?BUCY, R. Pat; KILBY, J. Michael.AIDS (Supplement). 2001, Vol 15, Num 2, pp S36-S42, issn 1350-2840Article

IMPACT OF A COMPUTER-ASSISTED, PROVIDER-DELIVERED INTERVENTION ON SEXUAL RISK BEHAVIORS IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) IN A PRIMARY CARE SETTINGBACHMANN, Laura H; GRIMLEY, Diane M; HONGJIANG GAO et al.AIDS education and prevention. 2013, Vol 25, Num 2, pp 87-101, issn 0899-9546, 15 p.Article

Patient Reported Outcomes in Routine Care: Advancing Data Capture for HIV Cohort ResearchKOZAK, Michael S; MUGAVERO, Michael J; KITAHATA, Mari M et al.Clinical infectious diseases. 2012, Vol 54, Num 1, pp 141-147, issn 1058-4838, 7 p.Article

Temporal Trends in Presentation for Outpatient HIV Medical Care 2000-2010: Implications for Short-term MortalitySEAL, Paula S; JACKSON, David A; MUGAVERO, Michael J et al.Journal of general internal medicine. 2011, Vol 26, Num 7, pp 745-750, issn 0884-8734, 6 p.Article

Uncompensated Medical Provider Costs Associated with Prior Authorization for Prescription Medications in an HIV ClinicRAPER, James L; WILLIG, James H; LIN, Hui-Yi et al.Clinical infectious diseases. 2010, Vol 51, Num 6, pp 718-724, issn 1058-4838, 7 p.Article

Virologic and immunologic response to HAART, by age and regimen classALTHOFF, Keri N; JUSTICE, Amy C; KLEIN, Marina B et al.AIDS (London). 2010, Vol 24, Num 16, pp 2469-2479, issn 0269-9370, 11 p.Article

Effect of Early versus Deferred Antiretroviral Therapy for HIV on SurvivalKITAHATA, Mari M; GANGE, Stephen J; ROURKE, Sean B et al.The New England journal of medicine. 2009, Vol 360, Num 18, pp 1815-1826, issn 0028-4793, 12 p.Article

Sustained HIV viral suppression following treatment interruption : An observational studyBEDIMO, Roger; CHEN, Ray Y; WESTFALL, Andrew O et al.AIDS research and human retroviruses. 2006, Vol 22, Num 1, pp 40-44, issn 0889-2229, 5 p.Article

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapyXIPING WEI; DECKER, Julie M; HONGMEI LIU et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 6, pp 1896-1905, issn 0066-4804Article

Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practiceCHEN, Ray Y; WESTFALL, Andrew O; RAPER, James L et al.AIDS research and human retroviruses. 2002, Vol 18, Num 13, pp 909-916, issn 0889-2229, 8 p.Article

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS society-USA PanelSCHAMBELAN, Morris; BENSON, Constance A; POWDERLY, William G et al.Journal of acquired immune deficiency syndromes (1999). 2002, Vol 31, Num 3, pp 257-275, issn 1525-4135, 19 p.Article

Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infectionCALL, Stephanie A; SAAG, Michael S; WESTFALL, Andrew O et al.The Journal of infectious diseases. 2001, Vol 183, Num 3, pp 401-408, issn 0022-1899Article

Early Retention in HIV Care and Viral Load Suppression: Implications for a Test and Treat Approach to HIV PreventionMUGAVERO, Michael J; RIVET AMICO, K; SAAG, Michael S et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 1, pp 86-93, issn 1525-4135, 8 p.Article

Pain, Mood, and Substance Abuse in HIV: Implications for Clinic Visit Utilization, Antiretroviral Therapy Adherence, and Virologic FailureMERLIN, Jessica S; WESTFALL, Andrew O; RAPER, James L et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 2, pp 164-170, issn 1525-4135, 7 p.Article

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/ Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRKROCKSTROH, Jiirgen K; LENNOX, Jeffrey L; DINUBILE, Mark J et al.Clinical infectious diseases. 2011, Vol 53, Num 8, pp 807-816, issn 1058-4838, 10 p.Article